The diagnosis of primary adenocarcinoma of the urinary bladder may be challenging in routine practice. These tumors may morphologically and immunohistochemically overlap with urachal adenocarcinoma and colorectal adenocarcinoma. Further, their genetic background is poorly understood. We systematically searched the PubMed database for results of complex genetic evaluation of primary bladder adenocarcinoma subtypes. Subsequently, we designed our own series of bladder lesions. We evaluated 36 cases: 16 primary enteric-type adenocarcinomas, 7 urachal enteric adenocarcinomas, 3 primary mucinous/colloid adenocarcinomas, and 10 intestinal-type metaplasia/villous adenoma. Detailed clinical data were collected, and all cases were examined using targeted next-generation sequencing. On the basis of the literature, the first mutated gene in these tumors was reported to be KRAS in 11.3% of cases, followed by TERT promoter mutations in 28.5%. In addition to KRAS and TERT, other genes were also found to be frequently mutated in primary bladder adenocarcinoma, including TP53, PIK3CA, CTNNB1, APC, FBXW7, IDH2, and RB1. In our series, the most frequent gene mutations in primary enteric-type adenocarcinomas were as follows: TP53 (56%); BRCA2, KMT2B (both 33%); NOTCH2, KDR, ARID1B, POLE, PTEN, KRAS (all 28%); in urachal enteric adenocarcinoma they were as follows: TP53 (86%); PTEN, NOTCH (both 43%); in primary mucinous/colloid adenocarcinomas they were as follows: KRAS, GRIN2A, AURKB (all 67%); and, in intestinal-type metaplasia/villous adenoma, they were as follows: APC, PRKDC (both 60%); ROS1, ATM, KMT2D (all 50%). No specific mutational pattern was identified using cluster analysis for any of the groups. Herein, we describe the pathologic features and immunohistochemical staining patterns traditionally used in the differential diagnoses of glandular lesions of the bladder in routine surgical pathology. We outline the mutational landscape of these lesions as an aggregate of published data with additional data from our cohort. Although diagnostically not discriminatory, we document that the most common genetic alterations shared between these glandular neoplasms include TP53, APC (in the Wnt pathway), and KRAS (in the MAPK pathway) mutations.

Cancer Biology and Epigenetics Group

Department of Pathology Centro Hospitalar de Vila Nova de Gaia Espinho Vila Nova de Gaia

Department of Pathology Centro Hospitalar e Universitário de São João Porto Portugal

Department of Pathology Faculty of Medicine University of British Columbia Royal Columbian Hospital Vancouver BC

Department of Pathology Institute Nacional de Cancerologia INCAN Mexico City Mexico

Department of Pathology Portuguese Oncology Institute of Porto

Department of Pathology School of Medicine Zagreb Croatia

Department of Pathology Sorbonne Université Service d'Anatomie et Cytologie Pathologiques Hôpital Tenon Paris France

Department of Pathology University of Calgary and Calgary Laboratory Services Calgary AB Canada

Departments of Microscopy

Departments of Pathology

Faculty of Medicine University of Porto

Pathology and Molecular Immunology Institute of Biomedical Sciences Abel Salazar University of Porto

Urology Charles University Prague Faculty of Medicine in Plzeň Plzeň Czech Republic

Zobrazit více v PubMed

Williamson SR, Lopez-Beltran A, Montironi R, et al. Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. Histopathology. 2011;58:811–834.

Moch H, Humphrey PA, Ulbright TM, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC; 2016.

Eble JN, Sauter G, Epstein JI, et al. World Health Organization Classification of Tumours Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC; 2004.

Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246–1255.

Taylor AS, Mehra R, Udager AM. Glandular tumors of the urachus and urinary bladder: a practical overview of a broad differential diagnosis. Arch Pathol Lab Med. 2018;142:1164–1176.

Amin MB, Trpkov K, Lopez-Beltran A, et al. Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: Report from the international society of urologic pathology consensus conference. Am J Surg Pathol. 2014;38:e20–e34.

Amin MB, Smith SC, Eble JN, et al. Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol. 2014;38:1033–1045.

Al-Ahmadie H, Netto GJ. Updates on the genomics of bladder cancer and novel molecular taxonomy. Adv Anat Pathol. 2020;27:36–43.

Lerner SP, McConkey DJ, Hoadley KA, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016;2:37–47.

Alexander RE, Lopez-Beltran A, Montironi R, et al. Kras mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology. 2012;61:1036–1042.

Cowan ML, Springer S, Nguyen D, et al. Detection of tert promoter mutations in primary adenocarcinoma of the urinary bladder. Hum Pathol. 2016;53:8–13.

Roy S, Pradhan D, Ernst WL, et al. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Mod Pathol. 2017;30:1133–1143.

Maurer A, Ortiz-Bruechle N, Guricova K, et al. Comparative genomic profiling of glandular bladder tumours. Virchows Arch. 2020. [Epub ahead of print].

Pires-Luis AS, Martinek P, Filipovic J, et al. Primary adenocarcinoma of the urinary bladder: next-generation sequencing (NGS) of nonurachal enteric-type adenocarcinomas, urachal adenocarcinomas, mucinous adenocarcinomas, and colonic metaplasias/adenomas. Mod Pathol. 2018;31(suppl 2):376.

Kim PH, Cha EK, Sfakianos JP, et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol. 2015;67:198–201.

Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857–865.

Landrum MJ, Lee JM, Benson M, et al. Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067.

Robinson JT, Thorvaldsdottir H, Wenger AM, et al. Variant review with the integrative genomics viewer. Cancer Res. 2017;77:e31–e34.

Lin JJ, Shaw AT. Recent advances in targeting ros1 in lung cancer. J Thorac Oncol. 2017;12:1611–1625.

Kurtis B, Zhuge J, Ojaimi C, et al. Recurrent tert promoter mutations in urothelial carcinoma and potential clinical applications. Ann Diagn Pathol. 2016;21:7–11.

Singh H, Liu Y, Xiao X, et al. Whole exome sequencing of urachal adenocarcinoma reveals recurrent nf1 mutations. Oncotarget. 2016;7:29211–29215.

Kardos J, Wobker SE, Woods ME, et al. Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype. JCO Precis Oncol. 2017:1–12.

Collazo-Lorduy A, Castillo-Martin M, Wang L, et al. Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol. 2016;70:771–775.